The Experts below are selected from a list of 1599 Experts worldwide ranked by ideXlab platform

Alexander V. Kabanov - One of the best experts on this subject based on the ideXlab platform.

  • pluronic block copolymers evolution of drug delivery concept from inert nanocarriers to Biological Response Modifiers
    Journal of Controlled Release, 2008
    Co-Authors: Elena V Batrakova, Alexander V. Kabanov
    Abstract:

    Polymer nanomaterials have sparked a considerable interest as vehicles used for diagnostic and therapeutic agents; research in nanomedicine has not only become a frontier movement but is also a revolutionizing drug delivery field. A common approach for building a drug delivery system is to incorporate the drug within the nanocarrier that results in increased solubility, metabolic stability, and improved circulation time. With this foundation, nanoparticles with stealth properties that can circumvent RES and other clearance and defense mechanisms are the most promising. However, recent developments indicate that select polymer nanomaterials can implement more than only inert carrier functions by being Biological Response Modifiers. One representative of such materials is Pluronic block copolymers that cause various functional alterations in cells. The key attribute for the Biological activity of Pluronics is their ability to incorporate into membranes followed by subsequent translocation into the cells and affecting various cellular functions, such as mitochondrial respiration, ATP synthesis, activity of drug efflux transporters, apoptotic signal transduction, and gene expression. As a result, Pluronics cause drastic sensitization of MDR tumors to various anticancer agents, enhance drug transport across the blood brain and intestinal barriers, and causes transcriptional activation of gene expression both in vitro and in vivo. Collectively, these studies suggest that Pluronics have a broad spectrum of Biological Response modifying activities which make it one of the most potent drug targeting systems available, resulting in a remarkable impact on the emergent field of nanomedicine.

  • pluronic block copolymers in drug delivery from micellar nanocontainers to Biological Response Modifiers
    Critical Reviews in Therapeutic Drug Carrier Systems, 2002
    Co-Authors: Alexander V. Kabanov, Valery Alakhov
    Abstract:

    : Pluronic block copolymers are recognized pharmaceutical excipients listed in the US and British Pharmacopoeia. The incorporation of drugs into Pluronic micelles results in increased solubility and stability of drugs. Consequently, the micelles are used for delivery of drugs in the body. Pluronic unimers sensitize multidrug-resistant cells by inhibiting drug efflux transporters. This allows for the development of formulations for the treatment of multidrug-resistant and metastatic tumors. Furthermore, these formulations can be used to enhance brain and oral bioavailability of various drugs. Finally, Pluronic formulations were shown to enhance transgene expression in the body. This opens new possibilities for the use of Pluronic in gene therapies.

Valery Alakhov - One of the best experts on this subject based on the ideXlab platform.

  • pluronic block copolymers in drug delivery from micellar nanocontainers to Biological Response Modifiers
    Critical Reviews in Therapeutic Drug Carrier Systems, 2002
    Co-Authors: Alexander V. Kabanov, Valery Alakhov
    Abstract:

    : Pluronic block copolymers are recognized pharmaceutical excipients listed in the US and British Pharmacopoeia. The incorporation of drugs into Pluronic micelles results in increased solubility and stability of drugs. Consequently, the micelles are used for delivery of drugs in the body. Pluronic unimers sensitize multidrug-resistant cells by inhibiting drug efflux transporters. This allows for the development of formulations for the treatment of multidrug-resistant and metastatic tumors. Furthermore, these formulations can be used to enhance brain and oral bioavailability of various drugs. Finally, Pluronic formulations were shown to enhance transgene expression in the body. This opens new possibilities for the use of Pluronic in gene therapies.

Nicolas P E Barry - One of the best experts on this subject based on the ideXlab platform.

Swapna Chaudhuri - One of the best experts on this subject based on the ideXlab platform.

  • facilitation of functional compartmentalization of bone marrow cells in leukemic mice by Biological Response Modifiers an immunotherapeutic approach
    Immunology Letters, 2001
    Co-Authors: Sujata Law, Swapna Chaudhuri, Debasish Maiti, Aparna Palit, Dwijesh Dutta Majumder, Kaustuv Basu
    Abstract:

    Abstract Biological Response Modifiers (BRMs) including interleukin-2 (IL-2), interferon-gamma (IFN-γ) and sheep erythrocytes (SRBC) protected N , N ′-ethylnitrosourea (ENU) induced leukaemic mice. Two cell types from the bone marrow were isolated in density specific gradient representing two distinct compartments, the low density cells being more CD34 positive than the high density group. Investigations with the functional efficacy of such compartments revealed significant improvement of cytotoxic efficacy and phagocytic burst at the high density compartment (HDC) level. The high density compartment was found to be more responsive towards the BRMs compared to the cells of the low density compartment (LDC). It was suggested that use of BRMs in vivo can stimulate a potent functional progenitor compartmentalization in normal as well as leukaemic mice. These observations are expected to help a logistic approach towards combined BRM therapy at the clinical level.

Cristina Prat - One of the best experts on this subject based on the ideXlab platform.

  • Impact of Host Genetics and Biological Response Modifiers on Respiratory Tract Infections.
    Frontiers in immunology, 2019
    Co-Authors: Alicia Lacoma, Lourdes Mateo, Ignacio Blanco, Maria J. Méndez, Carlos Rodrigo, Irene Latorre, Raquel Villar-hernández, José Domínguez, Cristina Prat
    Abstract:

    Host susceptibility to respiratory tract infections (RTI) is dependent on both genetic and acquired risk factors. Repeated bacterial and viral RTI, such as pneumonia from encapsulated microorganisms, respiratory tract infections related to respiratory syncytial virus or influenza, and even the development of bronchiectasis and asthma, are often reported as the first symptom of primary immunodeficiencies. In the same way, neutropenia is a well-known risk factor for invasive aspergillosis, as well as lymphopenia for Pneumocystis, and mycobacterial infections. However, in the last decades a better knowledge of immune signaling networks and the introduction of next generation sequencing have increased the number and diversity of known inborn errors of immunity. On the other hand, the use of monoclonal antibodies targeting cytokines, such as tumor necrosis factor alpha has revealed new risk groups for infections, such as tuberculosis. The use of Biological Response Modifiers has spread to almost all medical specialties, including inflammatory diseases and neoplasia, and are being used to target different signaling networks that may mirror some of the known immune deficiencies. From a clinical perspective, the individual contribution of genetics, and/or targeted treatments, to immune dysregulation is difficult to assess. The aim of this article is to review the known and newly described mechanisms of impaired immune signaling that predispose to RTI, including new insights into host genetics and the impact of Biological Response Modifiers, and to summarize clinical recommendations regarding vaccines and prophylactic treatments in order to prevent infections.